Lyramid Ltd and KineraLtd would themselves commercialise their IP including Advangen paying either as applicable for its Midkine for its Evolis range. The present "lifeline" would not be severed. Any other funding if required would be on commercial terms. However, the subsidiaries were never meant to bleed Cellmid. Good point Hobbit2233 I hope I've answered.
Lyramid Ltd and KineraLtd would themselves commercialise their...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.229M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 309518 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 379373 | 2 |
View Market Depth
| Last trade - 11.41am 31/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable